Neogen Chemicals releases Q2 & H1 FY26 earnings call transcript, updates on battery chemicals and governance.
Neogen Chemicals released Q2 & H1 FY26 earnings, reporting 8% revenue growth despite a plant outage. The company detailed battery chemical expansion, including a new LiPF6 salt JV, and corporate governance changes. FY26 battery chemical guidance was revised downwards.
The announcement outlines critical strategic initiatives in the high-growth battery chemicals sector, such as the Indo-Japan JV for non-FEOC compliant LiPF6 salt and key customer approvals, which are pivotal for the company's long-term growth trajectory and market positioning. Despite short-term delays and financial pressures, these strategic moves have a high impact on the company's future prospects.
The company reported positive revenue growth and strategic advancements in battery chemicals, including a significant JV and customer approvals. However, profitability was constrained by higher operating costs, increased finance costs, and the battery chemical revenue guidance for FY26 was substantially revised downwards due to demand and approval delays, leading to a balanced neutral sentiment.
* Neogen Chemicals Limited released the Earnings Conference Call Transcript for its Q2 & H1 FY26 financial results, held on November 10, 2025, at 5:00 p.m. IST. The transcript is available on the company's website. * For Q2 FY26, consolidated revenue reached ₹209 crore, an 8% increase year-on-year, driven by sustained demand and increased volume in both base and organolithium businesses. Gross profit improved by 16%, with a 350 basis points margin expansion. EBITDA for the quarter was ₹30 crore, and PAT was ₹3 crore, both affected by elevated operating costs, increased finance costs, and initial costs of Neogen Ionics. * The company demonstrated operational resilience by neutralizing the temporary impact of a Dahej plant outage through production relocation and outsourcing, though this incurred additional temporary costs. * Significant corporate governance enhancements were announced, including the separation of Chairman and Managing Director roles effective October 1, 2025. Mr. Anurag Surana was designated Non-Executive Chairman of Neogen Chemicals Ltd., and Mr. Sanjay Mehta as Non-Executive Chairman of Neogen Ionics Ltd. Mr. TCN Sai Krishnan was appointed Executive Director. * Strategic expansion in battery chemicals is progressing: the greenfield electrolyte facility's mechanical completion is anticipated by the end of calendar year 2025, with trial production and commercial production for electrolyte expected in H1 FY27 (April-September 2026), and electrolyte salt in H2 FY27 (October 2026-March 2027). * A leading Indian gigascale customer has completed the Production Part Approval Process (PPAP) for Neogen's Dahej plant for long-term commercial electrolyte supply. Provisional approval for lithium electrolyte salt has also been received from a key international customer, with final approval expected in Q4 FY26 (January-March 2026). * Neogen announced the formation of Neogen Morita New Materials Limited (NML), an Indo-Japan joint venture with Morita Investments Limited (MIL). NML, 80% owned by Neogen Ionics Ltd., will produce solid LiPF6 salt, a key ingredient for lithium-ion battery electrolyte. This non-FEOC compliant facility will cater to the rapidly expanding lithium-ion battery market, especially for US 45X tax credits. * The company secured financial flexibility by executing a private placement of ₹200 crore NCDs to fund growth projects and expedite the rebuilding of the Dahej organic plant. Consolidated debt stood at ₹1,078 crore, with a net debt of ₹900 crore, maintaining strong liquidity with ₹167 crore in liquid investments. * The FY26 battery chemical revenue guidance was revised downwards to ₹30-₹40 crore (from an earlier ₹300 crore) due to delays in electrolyte demand in India and final customer approvals for salt. FY27 battery chemical revenue is projected at ₹400-₹500 crore, with full utilization targeted by FY29 (₹2,400-₹2,900 crore revenue). * The base business remains on track for ₹850 crore in FY26 and targets ₹950-₹1,000 crore in FY27, with anticipated double-digit growth thereafter. * Peak debt is expected around ₹1,800 crore by FY28. The increase in inventory (₹130 crore) is to compensate for the ₹170-₹180 crore inventory lost in the Dahej fire. * Insurance payouts for the Dahej fire are ongoing, with an interim payment received for capex-related claims (₹80 crore) and the majority of stock-related claims expected in Q3 FY26 (October-December 2025). Loss of profit claims are anticipated in Q2 or Q3 FY27 (July-December 2026).
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.